financetom
Business
financetom
/
Business
/
Battery maker Microvast Q3 revenue beats estimates, driven by strong demand for battery solutions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Battery maker Microvast Q3 revenue beats estimates, driven by strong demand for battery solutions
Nov 10, 2025 2:32 PM

Overview

* Microvast ( MVST ) Q3 revenue rose 21.6% yr/yr, beating analyst expectations

* Adjusted net income for Q3 missed analyst expectations

* Adjusted EBITDA for Q3 missed analyst expectations

Outlook

* Company maintains 2025 revenue guidance of $450 mln to $475 mln

* Microvast ( MVST ) updates 2025 gross margin outlook to 32%-35%

* Company to complete Huzhou Phase 3.2 expansion by year-end

Result Drivers

* REVENUE GROWTH - Co attributes 21.6% revenue increase to strong demand for battery solutions

* GROSS MARGIN IMPROVEMENT - Co cites efficiency and product mix as reasons for 4.4 percentage point gross margin increase

* ADJUSTED EBITDA - Positive adjusted EBITDA of $21.9 mln reflects focus on profitability and operational excellence, per CEO Yang Wu

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $123.3 $120.02

Revenue mln mln (2

Analysts

)

Q3 Miss $11.9 $17.34

Adjusted mln mln (1

Net Analyst)

Income

Q3 Net -$1.5

Income mln

Q3 Miss $21.9 $25.13

Adjusted mln mln (2

EBITDA Analysts

)

Q3 $33.5

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electrical components & equipment peer group is "buy"

* Wall Street's median 12-month price target for Microvast Holdings Inc ( MVST ) is $5.50, about 10.4% above its November 7 closing price of $4.93

* The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wilson tennis racket maker Amer Sports beats Q1 estimates on robust demand
Wilson tennis racket maker Amer Sports beats Q1 estimates on robust demand
May 21, 2024
May 21 - Amer Sports ( AS ) topped market expectations for first-quarter revenue and profit on Tuesday, helped by higher pricing and robust demand for its popular sporting goods brands in China and the United States. The Wilson tennis racket maker also expects full-year earnings per share at the higher end of its prior forecast range of 30 cents...
InterRent REIT Secures TSX Approval for Normal Course Issuer Bid
InterRent REIT Secures TSX Approval for Normal Course Issuer Bid
May 21, 2024
08:21 AM EDT, 05/21/2024 (MT Newswires) -- InterRent Real Estate Investment Trust (IIP-UN.TO) said on Tuesday that it has secured approval from the Toronto Stock Exchange for a normal course issuer bid that will begin on May 23 and run to May 22, 2025. The bid allows InterRent to buy nearly 13.7 million trust units, or about 10% of the...
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab
May 21, 2024
08:20 AM EDT, 05/21/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Tuesday that the US Food and Drug Administration has reassigned the Prescription Drug User Fee Act goal date of the Biologics License Application for the subcutaneous formulation of Opdivo co-formulated with Halozyme's recombinant human hyaluronidase. The PDUFA goal date is now expected Dec. 29, 2024, compared with...
Market Chatter: Beyond Meat Products Phased Out by Carl's Jr. and Del Taco Amid Consumer Decline
Market Chatter: Beyond Meat Products Phased Out by Carl's Jr. and Del Taco Amid Consumer Decline
May 21, 2024
08:26 AM EDT, 05/21/2024 (MT Newswires) -- Beyond Meat ( BYND ) plant-based beef products are being phased out by Carl's Jr. and Del Taco Restaurants amid fading consumer interest, Bloomberg reported late on Monday. Carl's Jr. has removed the Beyond Burger from most of its locations as of April, the report said, citing a restaurant spokesperson. Jack in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved